Skip to content

Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With extraordinal NK/T cell lymphoma-a single center, prospective, open clinical trial

Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With extraordinal NK/T cell lymphoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800014813
Enrollment
Unknown
Registered
2018-02-07
Start date
2018-02-19
Completion date
Unknown
Last updated
2018-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extranodal NK/T-cell lymphoma

Interventions

Gold Standard:PET/CT, clinical outcome
Index test:serum&#32
ctDNA,&#32

Sponsors

Department of hematology, Second Affiliated Hospital, Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. aged = 18 years; 2. newly diagnosed non-Hodgkin's lymphoma (Extranodal NK/T-cell lymphoma) diagnosed independently by 2 pathologists without inert lymphoma (diagnostic criteria refer to WHO 2008 Criteria for classification of hematologic malignancies; 3. negative blood or urine pregnancy test; 4. normal blood biochemical examination (except those with abnormal organ function or biochemical index caused by lymphoma; 5. no serious damage to important organ function of the whole body; 6. sign informed consent independently.

Exclusion criteria

Exclusion criteria: 1. Have serious organ dysfunction; 2. Combined with other cancer need treatment; 3. Presence of clinical signs of brain dysfuntion or severe mental illness can not comply with the study protocol; 4. Can not scheduled follow-up

Design outcomes

Primary

MeasureTime frame
ctDNA;relapse;

Secondary

MeasureTime frame
Disease free survival;overall survival;

Countries

China

Contacts

Public ContactZhang Xi

Second Affiliated Hospital, Army Medical University

zhangxxi@sina.com+86 13808310064

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 26, 2026